Literature DB >> 7525458

Analysis of a naturally occurring HLA class I-restricted viral epitope.

K Falk1, O Rötzschke, S Stevanović, V Gnau, K Sparbier, G Jung, H G Rammensee, P Walden.   

Abstract

A previously described nonapeptide sequence motif for antigens recognized by T cells in the context of the human major histocompatibility complex (MHC) molecule HLA-A2.1 was used to identify the natural epitope of influenza A virus matrix protein. We show here that the peptide with the sequence GILGFVFTL is the synthetic analogue of the natural epitope by demonstrating the presence of the corresponding peptide on MHC molecules of virus-infected cells. The role of the hydrophobic anchor amino acids in positions 2 and 9, which constitute the epitope motif, was investigated with synthetic variants of the epitope and cytotoxic T lymphocytes as indicator cells. The crucial role of the side chains of amino acids in those positions was evidence by their influence on the efficiency of T-cell stimulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525458      PMCID: PMC1414868     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors:  A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

2.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

3.  Exact prediction of a natural T cell epitope.

Authors:  O Rötzschke; K Falk; S Stevanović; G Jung; P Walden; H G Rammensee
Journal:  Eur J Immunol       Date:  1991-11       Impact factor: 5.532

4.  Low affinity interaction of peptide-MHC complexes with T cell receptors.

Authors:  K Matsui; J J Boniface; P A Reay; H Schild; B Fazekas de St Groth; M M Davis
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

Review 5.  Cell biology of antigen presentation.

Authors:  J J Neefjes; F Momburg
Journal:  Curr Opin Immunol       Date:  1993-02       Impact factor: 7.486

6.  The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2.

Authors:  M A Bednarek; S Y Sauma; M C Gammon; G Porter; S Tamhankar; A R Williamson; H J Zweerink
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

Review 7.  Developmental biology of T cells in T cell-receptor transgenic mice.

Authors:  H von Boehmer
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

8.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

9.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2.

Authors:  F Gotch; J Rothbard; K Howland; A Townsend; A McMichael
Journal:  Nature       Date:  1987 Apr 30-May 6       Impact factor: 49.962

10.  Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site.

Authors:  F Gotch; A McMichael; J Rothbard
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more
  7 in total

Review 1.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

2.  Detection and quantification of CD4(+) T cells with specificity for a new major histocompatibility complex class II-restricted influenza A virus matrix protein epitope in peripheral blood of influenza patients.

Authors:  T Linnemann; G Jung; P Walden
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.

Authors:  F Kern; I P Surel; N Faulhaber; C Frömmel; J Schneider-Mergener; C Schönemann; P Reinke; H D Volk
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

4.  Cross-linking of Fc(gamma)-receptor on monocytes inhibits hepatitis C virus-specific cytotoxic T-lymphocyte induction in vitro.

Authors:  T Kanto; N Hayashi; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; M Hori
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

5.  Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells.

Authors:  Kamalakannan Rajasekaran; Va Xiong; Lee Fong; Jack Gorski; Subramaniam Malarkannan
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

6.  Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries.

Authors:  K Udaka; K H Wiesmüller; S Kienle; G Jung; P Walden
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

7.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.

Authors:  Annika Nelde; Tatjana Bilich; Jonas S Heitmann; Yacine Maringer; Helmut R Salih; Malte Roerden; Maren Lübke; Jens Bauer; Jonas Rieth; Marcel Wacker; Andreas Peter; Sebastian Hörber; Bjoern Traenkle; Philipp D Kaiser; Ulrich Rothbauer; Matthias Becker; Daniel Junker; Gérard Krause; Monika Strengert; Nicole Schneiderhan-Marra; Markus F Templin; Thomas O Joos; Daniel J Kowalewski; Vlatka Stos-Zweifel; Michael Fehr; Armin Rabsteyn; Valbona Mirakaj; Julia Karbach; Elke Jäger; Michael Graf; Lena-Christin Gruber; David Rachfalski; Beate Preuß; Ilona Hagelstein; Melanie Märklin; Tamam Bakchoul; Cécile Gouttefangeas; Oliver Kohlbacher; Reinhild Klein; Stefan Stevanović; Hans-Georg Rammensee; Juliane S Walz
Journal:  Nat Immunol       Date:  2020-09-30       Impact factor: 25.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.